

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4943830

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	08/01/2013
RECEIVING PARTY DATA	
Name:	OHIO STATE INNOVATION FOUNDATION
Street Address:	1524 NORTH HIGH STREET
City:	COLUMBUS
State/Country:	OHIO
Postal Code:	43201
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12389759
CORRESPONDENCE DATA	
Fax Number:	(404)645-7707
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4046457700
Email:	amsmith@mcciplaw.com
Correspondent Name:	MEUNIER CARLIN & CURFMAN LLC
Address Line 1:	999 PEACHTREE STREET NE
Address Line 2:	SUITE 1300
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	10336-395US1
NAME OF SUBMITTER:	ALYSSA SMITH
SIGNATURE:	/Alyssa Smith/
DATE SIGNED:	05/02/2018
Total Attachments: 3	
source=OSURF_OSIF Assignment of Patents#page1.tif	
source=OSURF_OSIF Assignment of Patents#page2.tif	
source=OSURF_OSIF Assignment of Patents#page3.tif	

ASSIGNMENT OF PATENTS

ASSIGNMENT OF PATENTS made as of the 1st day of August, 2013, by and between The Ohio State University Research Foundation ("Assignor") and Ohio State Innovation Foundation, an Ohio nonprofit corporation ("Assignee").

RECITAL

The Ohio State University ("OSU") and Assignee are parties to that certain Master Agreement dated as of August 1st, 2013 (the "Agreement") pursuant to which OSU has agreed to cause Assignor to transfer to Assignee and Assignee has agreed to receive and accept from Assignor the Transferred Existing IP (as defined in the Agreement), including, without limitation, all such patents and patent applications owned, either partially or wholly, by Assignor world-wide. Pursuant to the Agreement, OSU has agreed to cause Assignor to execute such instruments as Assignee may reasonably request in order to more effectively assign, transfer, grant, convey, assure and confirm to Assignee and its successors and assigns, or to aid and assist in the collection of or reducing to possession by Assignee of, all of such assets.

In accordance therewith, Assignor desires to transfer and assign to Assignee, and Assignee desires to accept the transfer and assignment of, all of Assignor's worldwide right, title and interest in, to and under Assignor's domestic and foreign patents and patent applications, including without limitation, the patents and patent applications listed on *Schedule A* annexed hereto and incorporated herein by reference (all of the foregoing being referred to herein as the "Patents").

NOW, THEREFORE, Assignor, for and in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt of which is hereby acknowledged, does hereby transfer and assign to Assignee, and Assignee hereby accepts the transfer and assignment of, all of Assignor's worldwide right, title and interest in, to and under the Patents, all rights to sue for infringement of any Patent, whether arising prior to or subsequent to the date of this Assignment of Patents, and any and all renewals and extensions thereof, including all rights of priority arising therefrom and in and to all provisional, non-provisional, divisional, and continuing applications, substitute, renewal, and reissue applications, directed to the same invention in the Patents that have been or will be filed in the United States and other countries of the world, that may hereafter be secured under the laws now or hereafter in effect in the United States and in any other jurisdiction, the same to be held and enjoyed by the said Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the said Assignor had this Assignment of Patents not been made (the "Assignment").

FURTHER, Assignor authorizes and requests the Commissioner of Patents to issue all Letters Patent for the patents and patent applications listed on *Schedule A*, as well as any and all divisionals, continuations, substitutes, and reissues thereof, to said Assignee, its assigns and legal representatives in their own name, in accordance herewith.

A2014-0203

FURTHER, Assignor hereby consents that a copy of this Assignment of Patents shall be deemed a full legal and formal equivalent of any document which may be required in any country as proof of the right of said Assignee to apply for, defend or enforce a Patent or other form of protection for said inventions in the Patents and to claim the aforesaid benefit of the right of priority.


Except to the extent that federal law preempts state law with respect to the matters covered hereby, this Assignment of Patents shall be governed by and construed in accordance with the laws of the State of Ohio without giving effect to the principles of conflicts of laws thereof.

IN WITNESS WHEREOF, Assignor has caused its duly authorized officer to execute this Assignment of Patents, and Assignee acknowledges receipt of the Assignment by signature of its duly authorized officer, as of the date first above written.

THE OHIO STATE UNIVERSITY
RESEARCH FOUNDATION

By: *Geoffrey S. Chatas*

P
I Geoffrey S. Chatas, Sr. Vice President For
Business & Finance, and CFO
The Ohio State University



OHIO STATE INNOVATION FOUNDATION

By: *Brian A. Cummings*

Name: Brian A. Cummings
Title: President

SCHEDULE A

Application No.	Application Date:	Patent No.	Issue Date	Title	Inventors	Atty. Ref.
10/597,022	06-18-2007	9,115,090	08-25-2015	ZN2+-CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS	Ching-Shih Chen et al.	10336-385US1
12/361,626	01-29-2009	8,318,808	11-27-2012	ZN2+-CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS	Ching-Shih Chen et al.	10336-385US2
11/315,077	12-22-2005	7,714,005	05-11-2010	SMALL MOLECULE BCL-XL/BCL-2 BINDING INHIBITORS	Ching-Shih Chen et al.	10336-384US1
11/315,569	12-22-2005	7,566,787	07-28-2009	SMALL MOLECULE CYCLIN D1 ABLATIVE AGENTS	Ching-Shih Chen	10336-388US1
11/570,966	10-31-2008	8,377,948	02-19-2013	NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE	Ching-Shih Chen et al.	10336-387US1
11/909,559	05-18-2010	8,633,161	01-21-2014	THERAPEUTIC AGENTS FOR THE TREATMENT OF LEUKEMIA	Danilo Perrotti et al.	10336-389US1
12/179,134	07-24-2008	8,039,502	10-18-2011	ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS	Ching-Shih Chen et al.	10336-391US1
12/302,953	05-01-2009	8,318,812	11-27-2012	THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES	John C. Byrd et al.	10336-386US1
12/389,759	02-20-2009	7,973,062	07-05-2011	ANDROGEN RECEPTOR-ABLATIVE AGENTS	Ching-Shih Chen et al.	10336-395US1
12/547,036	08-25-2009	8,153,680	04-10-2012	ALKYL INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS	Ching-Shih Chen et al.	10336-393US1
12/758,858	04-13-2010	8,461,362	06-11-2013	PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS	Ching-Shih Chen et al.	10336-396US1
13/267,943	10-07-2011	8,445,483	05-21-2013	ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS	Ching-Shih Chen et al.	10336-391US2
13/305,927	11-29-2011	8,309,768	11-13-2012	FTV720-DERIVED ANTICANCER AGENTS	Ching-Shih Chen et al.	10336-392US1
13/329,593	12-19-2011	8,546,397	10-01-2013	DNA METHYLATION INHIBITORS	Ching-Shih Chen et al.	10336-413US1
13/429,779	03-26-2012	8,680,133	03-25-2014	ALKYL INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS	Ching-Shih Chen et al.	10336-393US2
13/869,386	04-24-2013	8,741,944	06-03-2014	ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS	Ching-Shih Chen et al.	10336-391US3

PATENT